Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.


home / news releases / MGNX - Zai Lab commences study in China testing margetuximab in stomach cancer

MGNX - Zai Lab commences study in China testing margetuximab in stomach cancer

MacroGenics Inc.
The first patient has been dosed in a China-based Phase 2/3 study, MAHOGANY, evaluating Zai Lab's (ZLAB) margetuximab, combined with a checkpoint inhibitor, with or without chemo, for the first-line treatment of HER2-positive gastric cancer or gastroesophageal junction cancer.The PD-1 inhibitor will be either retifanlimab or tebotelimab, both developed by MacroGenics (MGNX).Margetuximab is an HER2-targeting monoclonal antibody. The company has exclusive development and commercialization rights in Greater China (also includes tebotelimab) under a 2018 agreement with MacroGenics.

For further details see:

Zai Lab commences study in China testing margetuximab in stomach cancer
Stock Information
Company Name: MacroGenics Inc.
Stock Symbol: MGNX
Market: NASDAQ
Website: macrogenics.com
Menu
MGNX MGNX Quote MGNX Short MGNX News MGNX Articles MGNX Message Board
Get MGNX Alerts

News, Short Squeeze, Breakout and More Instantly...